Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy Is Associated with Age-Normative Growth and Normal Adrenal Function

Erika L. Finanger, MD; Richard Finkel, MD; Krista Vandenborne, PT, PhD; H Lee Sweeney, PhD; Gihan Tennekoon, MBBS, MRCS, LCRP; Perry Shieh, MD, PhD; Sabrina W. Yum, MD; Maria Mancini, MHP; James MacDoungall, PhD; Joanne Donovan, MD, PhD

Oregon Health Sciences University, Portland, OR; Nemours Children’s Health System, Orlando, FL; University of Florida Health, Gainesville, FL; The Children’s Hospital of Philadelphia, Philadelphia, PA; University of California, Los Angeles, Los Angeles, CA; Catabasis Pharmaceuticals, Boston, MA

Background

Study Design

Results

Conclusion

- Treatment with edasalonexent was well tolerated and associated with age-appropriate growth patterns without negative impact on bone health or adrenal function.
- Muscle function and MRI assessment of muscle integrity by MRI showed slowing of disease progression compared to an off-treatment control period.
- Edasalonexent is a potential new treatment option for all patients affected by Duchenne, and it is being evaluated in young boys in the Phase 3 PosenMD Trial to determine whether it can slow disease progression and have positive effects on muscle and cardiac function as well as bone health.

Acknowledgements

- Patients and families
- Patient groups
- ImagingDMD staff
- Site staff
- Catabasis team
- Thanks to PPMD and MDA for generous grant support for patient travel

Patients and families

Presented at the 2020 PPMD Annual Conference

Questions? MedInfo@catabasis.com

Presented at the 2020 PPMD Annual Conference

Presented at the 2020 PPMD Annual Conference